Bioventix
Research Bioventix (BVXP) on Bullrun: market cap GBX 8.36B, P/E 11.3, dividend yield 9.0%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBVXP
- ExchangeLSE
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyGBX
- Market capGBX 8.36B
- P/E11.3
- Dividend yield9.0%
- Financial periodFY2025
- RevenueGBP 13.12M
- Revenue growth-3.6%
- Net incomeGBP 7.58M
- Free cash flowGBP 7.01M
- Gross margin90.9%
Valuation Snapshot
latest market cap is GBX 8.36B; P/E is 11.3; dividend yield is 9.0%.
Peer valuation comparison
Latest P/E is 11.35x versus a Healthcare sector median of 24.61x (53.9% below).
Latest dividend yield is 8.96% versus a Healthcare sector median of 1.84% (387.0% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 13.12M | GBP 7.58M | GBP 7.01M | 90.9% | 1.43 | GBP 5.08M | n/a | GBP 11.55M |
| FY2024 | GBP 13.61M | GBP 8.10M | GBP 8.33M | 93.2% | 152.86 | GBP 6.00M | n/a | GBP 12.00M |
| FY2023 | GBP 12.82M | GBP 8.37M | GBP 7.79M | 93.5% | 1.58 | GBP 5.72M | n/a | GBP 12.06M |
| FY2022 | GBP 11.72M | GBP 7.67M | GBP 7.55M | 93.9% | 1.46 | GBP 6.13M | n/a | GBP 11.82M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-09-26 | GBX 8.36B | 11.3 | 9.4% | 1.5 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 1.5 GBX, yield 9.0%.
| Year | Dividends/share |
|---|---|
| FY2025 | 150 GBP |
| FY2024 | 155 GBP |
| FY2023 | 152 GBP |
| FY2022 | 152 GBP |
| FY2021 | 143 GBP |
About Bioventix
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Bioventix's market cap?
Bioventix's market capitalization is GBX 8.36B.
What is Bioventix's P/E ratio?
Bioventix's price-to-earnings (P/E) ratio is 11.3.
Does Bioventix pay a dividend?
Bioventix has a dividend yield of 9.0%.
What does Bioventix do?
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment.